Infliximab-induced Thrombocytopenia in an Elderly Patient with Ileocolonic Crohnʼs Disease

Mocciaro, Filippo; Russo, Giuseppina; Mitri, Roberto Di; Marino, A.

doi:10.1002/ibd.22989

Cited by 8 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the use of anti‐TNF agents in heart failure (NYHA class III and IV), a common comorbid condition in the elderly population, is contraindicated . Anti‐TNF–induced thrombocytopaenia in elderly patients with CD has been reported after therapy with infliximab and adalimumab …”

Section: Medical Treatmentmentioning

confidence: 99%

Systematic review with meta‐analysis: inflammatory bowel disease in the elderly

Gisbert

Chaparro

2014

Aliment Pharmacol Ther

143

102

View full text Add to dashboard Cite

show abstract

Section: Medical Treatmentmentioning

confidence: 99%

Systematic review with meta‐analysis: inflammatory bowel disease in the elderly

Gisbert

Chaparro

2014

Aliment Pharmacol Ther

143

102

View full text Add to dashboard Cite

show abstract

“…A moderately low platelet count is relatively common upon exposure to these agents, but more severe thrombocytopenia has also been reported in a few patients. The drugs involved are efalizumab (anti-CD11a) [63,64], adalimumab [65] and infliximab (anti-TNF, tumor necrosis factor) [28,29], bevacizumab (anti-VEGF) [27,66], rituximab (anti-CD20) [30,31], natalizumab (anti-α 4 β 1 -integrin) [32], and immune checkpoint antibodies to program cell death receptor-1 (PD-1) or cytoxic T-lymphocyte antigen 4 (CTLA-4), such as nivolumab, pembrolizumab, or ipilimumab [33,67]. Although the clinical evolution in most cases suggests that antibodies are involved in platelet destruction, their presence has never been firmly demonstrated.…”

Section: Thrombocytopenia Induced By Platelet-specific Auto-antibodiesmentioning

confidence: 99%

Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia

Vayne

Guéry

Rollin

et al. 2020

JCM

View full text Add to dashboard Cite

Drug-induced immune thrombocytopenia (DITP) is a life-threatening clinical syndrome that is under-recognized and difficult to diagnose. Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin. Several different mechanisms have been identified in typical DITP, which is most commonly characterized by severe thrombocytopenia due to clearance and/or destruction of platelets sensitized by a drug-dependent antibody. Patients with typical DITP usually bleed when symptomatic, and biological confirmation of the diagnosis is often difficult because detection of drug-dependent antibodies (DDabs) in the patient’s serum or plasma is frequently not possible. This is in contrast to heparin-induced thrombocytopenia (HIT), which is a particular DITP caused in most cases by heparin-dependent antibodies specific for platelet factor 4, which can strongly activate platelets in vitro and in vivo, explaining why affected patients usually have thrombotic complications but do not bleed. In addition, laboratory tests are readily available to diagnose HIT, unlike the methods used to detect DDabs associated with other DITP that are mostly reserved for laboratories specialized in platelet immunology.

show abstract

Infliximab

2013

Reactions Weekly

View full text Add to dashboard Cite

Infliximab-induced Thrombocytopenia in an Elderly Patient with Ileocolonic Crohnʼs Disease

Cited by 8 publications

References 6 publications

Systematic review with meta‐analysis: inflammatory bowel disease in the elderly

Systematic review with meta‐analysis: inflammatory bowel disease in the elderly

Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia

Infliximab

Contact Info

Product

Resources

About